m7G-related gene signatures determine prognosis in triple-negative breast cancer

Triple-negative breast cancer (TNBC), which lacks targeted treatment options, continues to pose a major clinical hurdle. This study investigated the molecular complexities of TNBC, with a focus on m7G modifications, the immune microenvironment, and their influence on patient prognosis. An integrated analysis of m7G-related genes facilitated the creation of a risk model based on differentially expressed m7G-related genes, which effectively stratified patients with TNBC into low- and high-risk groups, with the low-risk group demonstrating a marked survival advantage. Immune cell infiltration analysis revealed substantial differences between risk groups, suggesting a potential association between m7G-related risk and immune landscape modulation. Genomic profiling identified distinct mutational patterns, with TP53 mutations predominant in the high-risk group and PIK3CA mutations in the low-risk group. Chemosensitivity analysis indicated the potential for tailored drug responses, highlighting the utility of the m7G-related risk score in guiding personalized therapeutic approaches. Additionally, a nomogram incorporating the risk score, stage, and M stage was developed, providing a valuable tool for predicting 3-, 5-, and 10-year survival probabilities.